Total trials
180
Active
17
Phase 3
2
Total enrollment
33,673
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Blood biomarkers | — | — | — | — | — | 1 | |
| Health | — | — | — | — | — | 1 | |
| DNA | — | — | — | — | — | 1 | |
| Mental well-being | — | — | — | — | — | 1 |
Next readouts
- 2040-01
Top conditions
- Healthy12
- Sarcopenia6
- Eating Behavior6
- Obesity6
- Hypertension6
- Aging5
- Irritable Bowel Syndrome5
- Cognitive Decline5
Frequently asked questions about Wageningen University
- How many clinical trials does Wageningen University have on ClinicalTrials.gov?
- Wageningen University is listed as the lead sponsor on 180 clinical trials in ClinicalTrials.gov, 17 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Wageningen University's trials are in Phase 3?
- 2 of Wageningen University's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Wageningen University focus on?
- Wageningen University's most-studied conditions on ClinicalTrials.gov are Healthy, Sarcopenia, Eating Behavior, Obesity, Hypertension.
- When are Wageningen University's next clinical trial readouts?
- Wageningen University has 1 upcoming primary-completion readout tracked here; the soonest is “Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)”, expected around 2040-01.